Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06158490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 20, 2025 (before its estimated February 10, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Feb 10, 2025 to Feb 10, 2026 Completion date: Feb 10, 2025 to Oct 10, 2026v4 Show 1 more changeShow less
    • Completion date: Feb 10, 2025 to Oct 10, 2026
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation Primary endpoint revised · Study sites: 0 to 1 · Start date changed from estimate of Dec 10, 2023 to Dec 27, 2023 · 3 morev3 Show 6 more changesShow less
    • Primary endpoint revised
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 10, 2023 to Dec 27, 2023
    • Interventions: JYP0061 Placebo (Drug), JYP0061 tablet Dose1 (Drug), JYP0061 tablet Dose2 (Drug) to JYP0061 15 mg (Drug), JYP0061 30 mg (Drug), Placebo (Drug)
    • Secondary endpoints expanded, about 12 words
    • Collaborators shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary endpoint revised Interventions: Experimental Drug JYP0061 (Drug) to JYP0061 Placebo (Drug), JYP0061 tablet Dose1 (Drug), JYP0061 tablet Dose2 (Drug) · Eligibility criteria shortened, about 40 words · Study arms: 2 to 3 · 2 morev2 Show 5 more changesShow less
    • Interventions: Experimental Drug JYP0061 (Drug) to JYP0061 Placebo (Drug), JYP0061 tablet Dose1 (Drug), JYP0061 tablet Dose2 (Drug)
    • Eligibility criteria shortened, about 40 words
    • Study arms: 2 to 3
    • Secondary endpoints shortened, about 3 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: * The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. * The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: * Be treated with either a low-dose or high-dose of JYP0061. * Undergo efficacy and safety evaluations as stipulated in the trial protocol.
Trial Details
NCT Number NCT06158490
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Moderate-to-severe Atopic Dermatitis
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov